Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1418609
This article is part of the Research Topic Advances in Drug-induced Diseases Volume II View all 22 articles

Comparative Safety Analysis of Lacosamide and Perampanel in Epilepsy Management: Insights from FAERS Database

Provisionally accepted
Chang Ge Chang Ge 1*Jin Liuyin Jin Liuyin 1Jing-Jing Tian Jing-Jing Tian 2Jian Xu Jian Xu 1Na Yang Na Yang 3Liuyin Jin Liuyin Jin 1
  • 1 Zhejiang University, Hangzhou, China
  • 2 Tsinghua University, Beijing, Beijing, China
  • 3 Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    Background: Epilepsy is a chronic neurological condition requiring effective management with minimal adverse effects. Lacosamide(LCM) and Perampanel(PER), two promising treatments, have distinct profiles that merit comparative analysis to guide clinical decision-making.Methods: This study utilizes a pharmacovigilance analysis of adverse events (AEs) reported in the FDA Adverse Event Reporting System (FAERS) database from Q1 2009 to Q3 2023. Employing disproportionality and Bayesian analyses, we assessed and compared the AE signals associated with LCM and PER to elucidate their safety profiles in epilepsy treatment.The analysis included 12,576 AE reports for LCM and 2,703 for PER, highlighting a higher incidence of psychiatric disorders, including aggression with LCM, and a notable association of PER with psychiatric disorders such as psychotic disorders and dizziness. LCM showed a relatively safe profile during pregnancy, whereas PER's data suggested caution due to reported cases of suicidal ideation and attempts.Conclusions: This comprehensive evaluation underscores the importance of understanding the distinct AE profiles of LCM and PER in clinical practice, providing valuable insights for personalized epilepsy management. Future research with rigorous prospective designs is recommended to validate these findings and explore the mechanisms underlying the reported adverse events.

    Keywords: Epilepsy, lacosamide, Perampanel, Pharmacovigilance, FAERS, adverse events

    Received: 16 Apr 2024; Accepted: 08 Aug 2024.

    Copyright: © 2024 Ge, Liuyin, Tian, Xu, Yang and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chang Ge, Zhejiang University, Hangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.